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Phosphatase and tensin homolog (PTEN) is the protein encoded by the PTEN gene (10q23.3). PTEN mutations are related
to a variety of rare diseases referred to collectively as PTEN hamartoma tumor syndromes (PHTS), which include Cowden
Syndrome, Bannayan-Riley-Ruvalcaba syndrome, Proteus Syndrome, and Proteus-like syndrome. These diseases are associated
with an increased risk of malignancy and for this reason an accurate and early diagnosis is essential in order to institute cancer
surveillance. PTEN is a regulator of growth and homeostasis in immune system cells, although there are limited data describing
immune dysregulation caused by PTEN mutations. We describe a case of PHTS syndrome caused by a de novo mutation in PTEN
detected using a targeted next generation sequencing (NGS) gene panel which was instigated for workup of cutaneous vasculitis.
We highlight the diagnostic utility of this approach and that mutations in PTEN may be associated with immune-dysregulatory
features such as vasculitis in young children.
1. Introduction
Phosphatase and tensin homolog (PTEN) is the protein
encoded by the PTEN gene, located on 10q23.3. PTEN is an
important tumor suppressor and is one of the most com-
monly mutated tumor suppressor genes reported in spo-
radic human cancer [1]. PTEN dephosphorylates phos-
phatidylinositol(3,4,5)P3 (PIP3) to phosphatidylinositol 4,5-
bisphosphate (PIP
2
), thus antagonizing pathways down-
stream of receptor tyrosine kinases and phosphatidylinositol-
3-kinase (PI3K). PTEN acts as a tumor suppressor gene by
negatively regulating PI3K-Akt and mammalian target of
rapamycin (mTOR) signaling pathways, which play a critical
role in cell proliferation and oncogenesis [2]. The class Ia
PI3K family contains three catalytic isoforms (p110a, p110b,
and p110d) encoded by three different genes, of which p110d
is restricted to the immune system, while p110a and p110b are
expressed in all tissues and organs [3, 4].
PTEN mutations are related to a variety of rare syn-
dromes, collectively known as PTEN hamartoma tumor
syndromes (PHTS), which include Cowden Syndrome (CS),
Bannayan-Riley-Ruvalcaba syndrome (BRRS), and Proteus
and related syndromes [5], although the latter association
remains somewhat controversial [6, 7]. CS is inherited in an
autosomal dominant fashion, although a proportion of cases
arise as a result of new mutations. Its incidence is approxi-
mately 1 : 200,000, and the most frequently described muta-
tions are point mutations, deletions, or insertions [8]. CS
has a heterogeneous clinical presentation [9]; clinical fea-
tures include multiple hamartomas, macrocephaly, typical
mucocutaneous lesions (trichilemmomas), acral keratosis,
glycogenic acanthosis of the oesophagus, and papillomatous
papules. PTEN mutations can sometimes be associated with
autistic spectrum disorders and developmental delay. It is
also associated with thyroid, breast, renal, and endometrial
manifestations, including cancer in all of these tissues. The
lifetime risk of developing gastrointestinal carcinoma in CS
is approximately 9% [10].
While most previous reports have focused on the tumor
suppressor role of PTEN, it is increasingly recognized that
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Figure 1: (a) Vasculitic rash with a distinct circinate pattern. (b) Photomicrograph of skin biopsy demonstrating inflammation affecting the
superficial and deep dermal small vessels, comprising predominantlymononuclear inflammatory cells, but with focal destruction of the vessel
walls with fibrin deposition, red cell fragmentation, and scattered nuclear fragments (haematoxylin and eosin, original magnification ×100).
immune dysregulation is also an important feature in some
patients with PTEN mutations. We describe a sporadic case
of possible PHTS associated with cutaneous vasculitis from
early in life. This latter clinical manifestation prompted
genetic screening with a targeted next generation sequencing
(NGS) gene panel, called the “vasculitis and inflammation
panel (VIP),” which screens for 166 monogenic immune-
dysregulatory and autoinflammatory diseases. The patient’s
parents provided written consent for all of the investigations
described in this report and the report itself.
2. Case Report
A three-year-old Caucasian boy was investigated for diffuse
vasculitic skin lesions (Figure 1(a)). His parents were unre-
lated; his mother was pregnant with the second child, and his
family history was otherwise unremarkable. He was born by
forceps delivery at 42 weeks following a pregnancy with nor-
mal antenatal scans.Hewalked independently at 19months of
age. His parents reported concerns that he had some social
communication difficulties; a formal assessment (aged 4
years) confirmed the presence of autistic spectrum disorder.
His pastmedical history included recurrent upper respiratory
tract infections (URTI; approximately 8–10 per annum),
including a severe episode of croup requiring brief admission
to intensive care at the age of two years for airway support.
Physical examination revealed macrocephaly (head circum-
ference > 97.5th centile) and an unusual vasculitic rash
with a distinct circinate pattern (Figure 1(a)). A skin biopsy
revealed thrombotic, lymphocytic vasculitis with an absence
of immune-complex deposition on immunofluorescence
(Figure 1(b)). Blood tests revealed normal inflammatory
markers (erythrocyte sedimentation rate, C reactive protein,
and serum amyloid A); negative autoantibodies (ANA, ENA,
and ANCA); normal renal and hepatic function; normal uri-
nalysis; normal immunoglobulin levels; and mild lymphope-
nia (total lymphocytes 1.34 × 109/L; reference range 2–9.5 ×
109/L). Routine fever gene Sanger sequencing for more
commonly encountered autoinflammatory diseases known
to cause skin rashes was negative for MEFV, MVK, NLRP3,
NOD2, and TNFRSF1A. Tonsillectomy, undertaken for recur-
rent upper airway compromise secondary to intercurrent
(presumed viral) infections, resulted in complete resolution
of the cutaneous vasculitis, compatible with a reactive or
“hypersensitivity” cutaneous lymphocytic vasculitis [11, 12].
The presence of macrocephaly, autistic spectrum disorder,
recurrent URTI, and cutaneous vasculitis prompted us to
screen him using a targeted next generation sequencing
(NGS) panel, which targets known 166 genes broadly asso-
ciated with immune dysregulation or vasculopathy, the vas-
culitis and inflammation panel [13].
3. Methods
The Agilent EArray online tool (https://earray.chem.agilent
.com/suredesign/) was used to design an NGS panel target-
ing 166 genes, grouped into nine broad clinical pheno-
types: autoinflammatory disease; monogenic vasculitis/vas-
culopathy; complement defects; monogenic lupus; haemo-
phagocytic lymphohistiocytosis; early-onset inflammatory
bowel disease; autoimmune lymphoproliferative syndromes;
monogenic stroke; and hereditary amyloidosis. The targeted
region includes coding exons, conserved noncoding exons,
upstream promoter regions, and splice sites. Captured and
indexed libraries (QXT Target Enrichment System) were
sequenced as a multiplex of 16 samples on an IlluminaMiSeq
sequencer in paired-end mode. Read alignment, variant
calling, and annotation were performed using Agilent Sure
Call v3.0 software.
4. Results
VIP targeted sequencing revealed a mutation in the PTEN
gene, NM_000314; c.650T>A, p.V217D, which encodes for
phosphatase and tensin homolog protein, dominantmutation
of which is associated with CS [14], and related entities. This
was confirmed with Sanger sequencing and predicted to be
damaging by 3 widely used computational tools: SIFT, Poly-
Phen2, andMutationTaster [15–17]. No other class 4 or class 5
genetic variants were detected. Neither parent had this var-
iant (screened with Sanger sequencing), consistent with a
de novo mutation in the index case. His (now born) male
sibling had normal development at age 6 months and normal
head circumference and has thus not been screened for this
mutation.
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5. Discussion
We report a case of possible PHTS caused by heterozygous
mutation in PTEN characterized by the presence of social
communication difficulty, macrocephaly, recurrent URTI,
and early-onset cutaneous vasculitis, using a targeted NGS
panel (VIP).
Chen et al. recently described the immune dysregulation
in patientswith PHTS. Seventy-nine patientswith pathogenic
germline PTEN mutations underwent detailed immunologi-
cal studies, which demonstrated the presence of T- and B-cell
dysfunctions such as dysregulation, lymphopenia, increased
transitional B-cell counts, and reduced CD4/CD8 ratio [18].
PTEN is an important tumor suppressor gene but also
plays a role in immunematuration and function.Thep.V217D
PTEN mutation we identified has previously been described
as causing CS [14] and accounts for the macrocephaly and
autistic spectrum disorder; although recurrent severe URTI
have been described anecdotally in PHTS [19], whether or not
the PTEN variant directly accounts for recurrent infection
in our patient remains speculative. Similarly, we also cannot
conclude definitively that the reactive lymphocytic vasculitis
we observed was caused by immune dysregulation associ-
ated with this PTEN mutation, although it is increasingly
recognized that PTEN plays an important role in the immune
system (and itwas the reasonwe included this gene in ourVIP
gene panel). Indeed both immunodeficiency and autoim-
munity are lesser-known features in some patients with CS
and related conditions [19, 20]. Furthermore, the vasculitis
resolved completely following tonsillectomy, compatible with
an aberrant host immunological response to intercurrent
infection. Since immunodeficiency has been described in a
few cases of CS, and PTEN is an important regulator of B-, T-,
and NK-cell function, we speculate that lymphocytic vasculi-
tis was probably linked to this genetic mutation, although the
exact mechanism remains uncertain. Thus this hypothesis is
plausible but at the moment unconfirmed in our patient.
Browning et al. described two cases of CS with recurrent
URTI and B- and T-cell dysregulation [19]. The first case was
a five-year-old boywithmacrocephaly andmild developmen-
tal delay associated with heterozygous mutation (c.203A>G,
p.Y68C) of PTEN. Immunological investigations showed
pan-hypogammaglobulinemia, including absence of anti-
bodies to HIB despite vaccination, although he was able to
mount a short-lived protective antibody response to uncon-
jugated pneumococcal vaccine. Peripheral blood lymphocyte
immune-phenotyping revealed increased numbers of T-,
polyclonal-B-, NK-, CD5 and CD10 B-cells. Western blot
analysis in peripheral blood T-cells demonstrated a low
PTEN level and increased Akt and S6 phosphorylation fol-
lowing stimulationwith anti-CD3 or anti-CD28. After activa-
tion, the patient’s T-cells had a higher levels of PIP
3
[19]. The
second case was a ten-year-old boy with heterozygous non-
sense mutation (c.87T>A) in PTEN which encodes a STOP
codon in place of a tyrosine at amino acid position 29 in
the PTEN protein, with macrocephaly and recurrent URTI.
Lymphocyte immune-phenotype profile showed mild CD4
and CD8 lymphopenia but normal levels of B- and NK-cells
[19].
Suzuki et al. studied how PTEN influences the regulation
of B-lymphocytes in B-cell-specific PTEN-mutatedmice [21].
Murine PTEN-deficient B cells were resistant to apoptotic
and migratory stimuli and demonstrated defective immuno-
globulin class switching, emphasizing a role for PTEN in the
regulation of B cells [21]. Furthermore, mice with T-cell-
specific deficiency in PTEN have dysregulated thymic T-cell
proliferation and excessive T-cell activation, which con-
tributed to not only the development of tumors, but also
autoimmunity in this animal model [22]. PTEN is also a neg-
ative regulator of cytolytic function in NK-cells. A study of
PTEN expression and its function in human andmurine NK-
cells demonstrated that immatureNK-cells with low cytolytic
activity have higher PTEN expression than mature NK-cells
and that a decrease in PTEN activity causes an increase
in cytolytic NK-cell function [23]. Since dominant gain-of-
function mutations in PIK3CD cause humoral immunodefi-
ciency, lymphopenia, recurrent URTI, and lymphoid hyper-
plasia [24, 25], and PTEN regulates PI3K [26], it has been
suggested that heterozygous mutation of PTEN results in
immune dysregulation which shares some features of PI3K𝛿
immunodeficiency. This latter syndrome is characterized by
increased catalytic function of PI3K𝛿 that induces a primary
immunodeficiency, with similar albeit more severe clinical
presentation than the immunodeficiency described in CS
[27].
There are limited reports of autoimmunity in CS; Heindl
et al. described a series of 34 patients with PTEN mutations
with miscellaneous autoimmune or immune-dysregulatory
manifestations including gastrointestinal lymphoid hyper-
plasia, hyperplastic tonsils (reminiscent of our case), thy-
mus hyperplasia, lymphocytic thyroiditis, autoimmune hae-
molytic anaemia, and colitis [20]. To the best of our knowl-
edge, our case is the first report of possible PHTSwith vasculi-
tis, investigation of which ultimately led to the correct molec-
ular diagnosis. Thus far, tonsillectomy has been a successful
treatment for our patient, by reducing severity and frequency
ofURTI and resulting in complete resolution of the cutaneous
vasculitis; however the diagnosis of PHTS has important
lifetime consequences due to an increased lifetime cancer
risk, irrespective of minor autoimmune sequelae. Thus life-
long surveillance for cancer is mandatory. Tan et al. suggest
that paediatric patients with PTEN mutations under 18 years
of age should undergo annual targeted history and physical
examinations from diagnosis, including baseline thyroid
examinationswith ultrasound, and additional bespoke cancer
screening programmes for males and females into adulthood
[10].
In conclusion, this case report emphasizes the diagnostic
utility of NGS, which resulted in the diagnosis of PHTS
caused by sporadic heterozygous mutation in PTEN, provid-
ing a unifyingmolecular cause to explain seemingly unrelated
and diverse clinical features. The immunological features of
CS and other PTEN related diseases (immunodeficiency +/−
autoimmunity) may be the initial presenting feature in young
children, as illustrated by our patient. While the cutaneous
vasculitis we observed has a seemingly benign prognosis
(thus far), PHTS carries an increased lifetime risk of malig-
nancy, and thus timely diagnosis is essential to institute
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lifelong cancer surveillance [28]. We acknowledge that this
case does not prove a causal relationship of this PTEN variant
and reactive vasculitis but does emphasize an emerging
hypothesis regarding a possible link between PTEN and
immune dysregulation worthy of future study.
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